NovaBay Pharmaceuticals Announces Laboratory Results Confirm Avenova Kills SARS-CoV-2 (COVID-19 Virus)
July 13 2020 - 5:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
testing results from an independent third-party laboratory
confirming that Avenova®, NovaBay’s proprietary formulation of pure
hypochlorous acid, kills SARS-CoV-2. Test results will be submitted
to the Environmental Protection Agency (EPA) for the EPA’s approved
list of disinfectants for use against SARS-CoV-2.
“Since Avenova’s inception, we have known it to be a powerful
antimicrobial spray solution, effective against all types of
pathogens, including a wide variety of viruses, bacteria, and
fungi. Now we have results from a highly reputable independent
laboratory confirming Avenova kills the coronavirus that causes
COVID-19,” said Justin Hall, NovaBay CEO.
The study was designed to determine Avenova’s effectiveness
against the SARS-CoV-2 on a hard surface. Testing was performed
with the USA-WA1/2020 strain of SARS-CoV-2 at room temperature (20
degrees Celsius [68 degrees Fahrenheit] +/- 1 degree) in a 5.0%
serum in viral inoculum on a glass Petri dish. Avenova (active
ingredient of 0.01% hypochlorous acid in saline solution) was
sprayed on the surface from a distance of six to eight inches until
the surface was thoroughly wet. Results at 60 seconds prove
Avenova’s ability to fully inactivate the virus.
“Most COVID-19 transmission is likely due to person-to-person
contact as respiratory droplets containing the virus spread through
the air by speaking or even breathing, and reach others in close
proximity. These large droplets transmit the virus by entering the
body typically through the eyes, nose or mouth,” explained Mr.
Hall.
“Avenova, formulated with our pure, FDA-cleared hypochlorous
acid, is completely non-toxic and is safe for use on all skin
surfaces, including delicate facial skin around eyes, nose and
mouth. As a cautionary note, I would like to warn consumers that
not all hypochlorous acid products are alike. Some are not designed
for use on skin the way Avenova is, and others are not as pure and
should not be used on skin on a daily basis. Additionally, some
hypochlorous acid products are not of a high pharmaceutical grade
like ours and may not maintain a sufficiently high concentration of
hypochlorous acid to kill SARS-CoV-2.”
Avenova is available without a prescription on Amazon and on
Avenova.com. Bulk orders by doctors and medical institutions can be
placed by calling 1-800-890-0329 or by emailing
sales@novabay.com.
As previously announced, NovaBay continues to work with the U.S.
Food and Drug Administration (FDA) on the Emergency Use
Authorization (EUA) for the fluorecare® SARS-CoV-2 IgG & IgM
Antibody Combined (colloidal gold chromatographic immunoassay) Test
Kit. The FDA has not provided a timeline for completion of the
review.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market and NEUTROPHASE® for the wound care market.
Avenova is the only lab-tested, truly pure Hypochlorous Acid that
is patented and FDA cleared. Avenova is made in the USA.
Forward-Looking Statements and Disclaimers
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our ability to obtain approval for
Avenova to be listed on the EPA’s list of disinfectants, the use of
Avenova as relates to COVID-19 and the impact such approval and
usage may have on our future financial results. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results or achievements to be materially
different and adverse from those expressed in or implied by the
forward-looking statements. Factors that might cause or contribute
to such differences include, but are not limited to, risks and
uncertainties relating to further consumer acceptance of Avenova,
and any potential damage to our established goodwill in the
marketplace. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings with the
Securities and Exchange Commission, especially under the heading
“Risk Factors.” The forward-looking statements in this release
speak only as of this date, and NovaBay disclaims any intent or
obligation to revise or update publicly any forward-looking
statement except as required by law.
No statements contained in this press release are meant to infer
that Avenova is a treatment for COVID-19 or that the use of Avenova
would prevent the contraction of the disease. There is no known
treatment, nor is there an FDA approved treatment for COVID-19. The
study completed was in-vitro only and did not involve live
subjects. The data reflects Avenova’s effectiveness against the
virus on a hard surface, not skin.
Socialize and Stay informed on
NovaBay’s progress
Like us on Facebook Follow us on Twitter Connect
with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing Information For NovaBay Avenova
purchasing information: Please call 800-890-0329 or email
sales@avenova.com. www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200713005206/en/
NovaBay Contact Justin Hall Chief Executive Officer and
General Counsel 510-899-8800 jhall@novabay.com
Investor Contact LHA Investor Relations Jody Cain
310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024